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We have hypothesized that post-infarction cardiac remodeling can be influenced by shifts in
the balance between intracellular mediators of “pathologic” and “physiologic” hypertrophy.
Although alpha1 adrenergic receptors (alpha1-ARs) mediate pro-adaptive hypertrophy dur-
ing pressure overload, little is known about their role or downstream mediators after myocar-
dial infarction.
Methods
We performed loss-of-function experiments via coronary ligation in alpha1A-AR knockout
(AKO) mice. Post-myocardial infarction (MI) remodeling was evaluated via echocardiogra-
phy, quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis of car-
diac fetal gene expression, histologic analysis of myocyte size, post-MI fibrosis and
apoptosis, and Western blot analysis of apoptotic regulators.
Results
Alpha1A-AR knockout paradoxically increased post-MI hypertrophy compared to wild type
controls (WT), but also increased ventricular dilatation, fibrosis, apoptosis, and 4-week post-
MI mortality (64% in AKO vs. 25% in WT, P = 0.02), suggesting a shift toward greater patho-
logic hypertrophy in the absence of pro-adaptive alpha1A effects. alpha1A-AR knockout
increased phospho-p38 levels in the pre-MI myocardium compared to WT (0.55 ± 0.16 vs.
0.03 ± 0.01, P<0.05) but decreased phospho-ERK1/2 post-MI (0.49 ± 0.35 arbitrary units vs.
1.55 ± 0.43 in WT, P<0.05). Furthermore, expression of pro-apoptotic factor Bax was
increased (1.19 ± 0.15 vs. 0.78 ± 0.08, P<0.05) and expression of anti-apoptotic factors
Bcl2 was decreased (0.26 ± 0.01 vs. 0.55 ± 0.06, P<0.01) compared to WT.
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Conclusions
Alpha1A-AR provides an important counterbalance to pathologic pathways during post-MI
remodeling that may be mediated through ERK1/2 signaling; these observations provide
support for further development of an alpha1A-AR/ERK-based molecular intervention for
this chronic, often fatal disease.
Introduction
We have hypothesized that a dynamic balance exists between signaling pathways during the
heart’s response to various stresses, with pro-adaptive pathways dominating in the context of
physiologic hypertrophy (e.g. in response to exercise or pregnancy), and greater mal-adaptive
signaling resulting in eventual decompensatory changes (e.g. in pressure overload or post-
infarction cardiomyopathy) [1,2]. Such a dynamic balance creates an opportunity for more
precise design of molecular interventions for progressive, often intractable heart failure, one of
the largest single sources of morbidity and mortality in the United States.
The adrenergic signaling system can influence both physiological and pathological cardiac
hypertrophy, particularly via the stimulation of different adrenergic receptors (ARs). Chronic
administration of a beta-AR agonist to rats with compensated concentric hypertrophy has
implicated beta-AR signal activation in the development of pathological hypertrophy, while
activation of G-protein-coupled alpha1- adrenergic receptors (alpha1-ARs) has been linked to
physiological hypertrophy [3,4]. It is well documented that three alpha1-AR subtypes, 1A/C,
1B and 1D, are expressed in cardiovascular tissues and play important roles in the regulation
of various physiological process, such as cardiac contractility, blood pressure regulation, and
the growth and proliferation of vascular smooth muscle cells [5–7].
Two of the alpha1-AR subtypes are predominantly expressed in the heart, alpha1A and
alpha1B, and both have been shown to regulate cardiac contractility via suppression of Ca2+
transients, increased myofilament Ca(2+)-sensitivity, and altered myofilament function [8,9].
Studies using the alpha1A knockout mouse model also showed that these specific receptors are
required for physiological cardiac hypertrophy [10]. The deletion of both alpha1A and alpha1B
receptors resulted in an exacerbation of the maladaptive response to pressure overload, with
increases in apoptosis, dilated cardiomyopathy, and death, suggesting that they might play an
ameliorative role counterbalancing other pathologic stimulation. Among the alpha1-AR sub-
types, alpha1A-ARs have been demonstrated to play a particularly important role in ischemic
preconditioning, and in suppression of cardiac myocyte apoptosis and activation of pro-survival
mitogen activated protein kinase (MAPK) signaling [11–13]. Furthermore, gain-of-function
studies have documented that enhanced inotropy from transgenic alpha1A-AR overexpression
prevents remodeling of the left ventricle (LV), preserves function, and reduces acute heart fail-
ure death after MI or induction of pressure overload [14,15].
Studies from our laboratory and others’ have indicated that numerous members of the
mitogen activated protein (MAP) kinase family play important roles in the remodeling of
left ventricle after myocardial infarction (MI) [2,16,17]. Earlier studies indicated that the
alpha1A-AR is the primary receptor subtype responsible for AR-induced activation of pro-sur-
vival and pro-adaptive MAP kinases MAP kinase/extracellular signal-related kinase (ERK)
kinases 1/2 (MEK1/2)-ERK1/2 in the myocardium [13,18]. We have postulated that the heart
possesses a repertoire of responses to various forms of stress, and that the characteristic revers-
ible, adaptive physiologic responses to certain stresses (e.g. exercise or pregnancy) are regulated
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by a differential balance of signaling factors compared to maladaptive pathologic responses to
others (e.g. MI or pressure overload). In this study, we hypothesized that in the absence of adap-
tive hypertrophic signaling mediated by the alpha1A-AR, an increase in the balance favoring
pathologic signaling would lead to a decline in pro-adaptive, physiologic remodeling after MI,
and subsequently to a corresponding exacerbation of pathologic post-MI remodeling. We
examined patterns of pathologic remodeling post-MI in the alpha1A-AR knockout mouse
(AKO), including functional/structural changes, changes in patterns of fetal gene expression,
and changes in apoptosis signaling and apoptosis rates.
Methods
Alpha1A-AR knockout model and mouse coronary artery ligation
The global alpha1A-AR knockout mouse line was generated by Dr. Simpson’s laboratory and
its phenotype has been described previously [19]. The AKO mouse has previously been found
to be normotensive, and no obvious phenotypic changes have been observed in unstressed
AKO mice [20]. Wild type (WT) and AKO male mice (8–10 weeks old) were anesthetized with
1.5% isoflurane using a rodent ventilator (Harvard) at 115 breaths/min. A left lateral thoracot-
omy incision was placed at the level of the fourth interspace and a 7.0 polypropylene suture
was used to ligate the left anterior descending artery (LAD). A sodium hyaluronate-carboxy-
methyl cellulose membrane patch (Seprafilm1, Genzyme) was placed between the left ventri-
cle and chest wall to facilitate reoperation. The left chest was then closed and the animal was
recovered in a light-warmed incubator after extubation. Buprenorphone (0.1 mg/kg) was
administered every 4–6 hours for evidence of pain. All animals were housed in sterile rodent
microisolator caging under standard rodent husbandry conditions, and all procedures con-
formed strictly with the Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85–23, revised 1996), and were approved
by the Institutional Animal Care and Use Committee of University of California, San Fran-
cisco (UCSF IACUC approval # AN107727-02). All surgery was performed under isoflurane
anesthesia to minimize cardiodepressive effects, and all efforts were made to minimize suffer-
ing. All animals were monitored at least twice daily for signs of distress; animals demonstrating
progressive weight loss, diminished food intake, lethargy or inactivity were monitored more
frequently. Animals showing signs of extensive wasting (>15% weight loss), inactivity, labored
breathing weakness or slow movement were euthanized within 12 hours via pentobarbital
injection (75 mg/kg, i.p.). Personnel involved in animal experiments underwent training in the
observation, recognition, and documentation of the intervention point parameters, and in the
humane handling of laboratory animals, and all had over 7 years experience in rodent care.
Treatment of post-MI remodeling with captopril
Where indicated in the text, the angiotensin converting enzyme (ACE) inhibitor captopril
(West-ward Pharmaceutical Corporation, Eatontown, NJ) was administered in the drinking
water (2g/L) of randomly selected animals from the time of LAD ligation until sacrifice of the
animal at 4 weeks post-MI [21]. Drinking water was changed 3 times per week. This dosing
regimen has not been associated with changes in blood pressure in past studies [21].
Echocardiography
Transthoracic echocardiography was performed in conscious mice 4 weeks post-MI using an
Acuson Sequoia 512 machine and a 13-MHz probe. A two-dimensional short-axis view of the
left ventricle was obtained at the level of the papillary muscles (i.e. remote to the infarction)
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and two-dimensional M-mode tracings were also recorded. LV fractional shortening was cal-
culated as (LVDd–LVDs)/LVDdX100, where LVDd = LV diastolic dimension and LVDs = LV
systolic dimension. EF ejection fraction was calculated as (EDV-ESV)EDV where EDV = end
diastolic volume and ESV = end systolic volume.
Tissue harvest and Western blot
Four weeks after LAD ligation, mice were anaesthetized with pentobarbital (75 mg/kg, i.p.)
prior to diastolic arrest via injection with 1 ml of 1M KCl (with 100 U heparin). Then the
hearts were perfused for 10 minutes with phosphate buffered saline with 100U/ml heparin.
Non-infarcted base halves of left ventricles for Western blot were snap frozen in liquid nitro-
gen, while other tissues were fixed in 10% paraformaldehyde for histology.
Snap frozen hearts were weighed and added to homogenization buffer containing 0.13 M
KCI, 1 mM EDTA, 1mM Na3(VO4), 5 mM NaF, 20 mM HEPES and Roche Complete Prote-
ase Inhibitor, then homogenized on ice. The homogenate was centrifuged at 16,000g for 20
minutes, and the resultant supernatant was used to determinate protein concentration and
kept in -80˚C. Tissue lysate (10microgram/well) from each heart was separated by electropho-
resis on 4–12% Bis-Tris gels. Separated proteins were then blotted to PVDF membranes. The
blot was blocked by 5% non-fat milk, then incubated with primary antibody overnight at 4˚C,
followed by incubation with a species-appropriate horseradish peroxidase-conjugated second-
ary antibody (AnaSpec). Protein expression on the blots was detected by ECL plus Western
blotting detection system (Amersham), and was analyzed by NIH ImageJ software.
mRNA measurements
RNA samples were extracted from non-infarcted LV tissue with Total RNA Purification Sys-
tem (Invitrogen). For cDNA syntheses, 500 ng of total RNA was reverse-transcribed using
M-MLV reverse transcriptase (Promega). Reactions were incubated for 60 min at 37˚C accord-
ing to the manufacturer’s protocols. SYBR Green real-time PCR analyses of mouse alpha myo-
sin heavy chain (alphaMHC), betaMHC, atrial natriuretic peptide (ANP) and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) in the cDNA samples was conducted in an ABI 7700
Sequence Detection System (Applied Biosystems) with 5% of the RT product, primers at 100
nM and SYBR Green Master (ABI). Primers used in the PCR were alphaMHC, 5’-gtcatc
cagtactttgccagc-3’and 5’-tcaatggaggccacggacac-3’; betaMHC, 5’-ttg
agaatccaaggctcagc-3’; ANP, 5’-gagaagatgccggtagaagatg-3’ and 5’-gag
cactgccgtctctcaga-3’; and GAPDH, 5’-catggccttccgtgttccta-3’ and 5’-
cctgcttcaccaccttcttgat-3’. Relative levels of mRNA expression of each gene were
normalized separately using GAPDH gene expression as loading controls.
Histologic analysis
Five-micron sections of paraffin-embedded hearts were stained with Texas Red-conjugated
wheat germ agglutinin (WGA, Invitrogen) and Sirius Red (Sigma) to assess myocyte size and
fibrosis in the septal myocardium remote to the LV infarct. All acquired images were analyzed
and compared using the ImageJ Software (Bethesda, MA, USA). Sections were also subjected
to TUNEL staining (ApopTag Peroxidase In Situ Apoptosis Detection Kit, Chemicon, Temec-
ula, CA), and apoptotic cells and total cells, identified via hematoxylin nuclear counterstaining,
were counted in 3 sections/heart. Hematoxylin-eosin staining was used to distinguish the mor-
phology of cells containing apoptotic nuclei on adjacent sections. The level of apoptosis is
expressed as apoptotic cells as a percentage of total nuclei.
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Data analysis
Results are expressed as mean ± SEM. Mean values were compared by the unpaired 2-tailed
Student’s t test for 2 groups. Sample size calculations were based on end point estimates from
previous studies. Survival curves of groups were plotted using the Kaplan-Meier method and
compared by the log-rank test. P-values less than 0.05 were considered statistically significant.
Results
Loss of alpha1A receptor modulates MAPK signaling in the pre- and
post-MI myocardium
Pro-survival and pro-adaptive MEK1/2-ERK1/2 MAP kinase signaling has been associated
with alpha1A-AR in the myocardium, and the impact of deletion of this receptor on MAPK
signaling was therefore investigated. Loss of alpha1A receptor did not result in a decrease of
phospho-ERK1/2 (P-ERK1/2) or of the ratio of P-ERK1/2:total ERK1/2 in sham control mice.
However, there was significantly higher expression of p38 (P<0.05), associated with an
increase in phospho-p38 and in its phosphatase regulator MKP1 (P<0.05), in AKO-sham
myocardium compared to WT-sham myocardium (Fig 1). Myocardial infarction induced sig-
nificant increases in the expression of MEK-1, phopho-MEK1, MAP Kinas phosphatase-3
(MKP3) and also phospho-p38 in the non-infarcted, remote myocardium of hearts subjected
to LAD ligation, compared to the myocardium of non-MI mice from both WT and AKO con-
trols (P<0.01, Fig 1), but this increase in MEK1 activation did not result in a significant change
in downstream ERK1/2 phosphorylation. Interestingly, loss of alpha1A-AR was associated
with down-regulation of phospho-ERK1/2 and a reduction in the phospho-ERK1/2: total
ERK1/2 ratio in the post-MI remote myocardium (Fig 1; P<0.05). Although the expression of
Fig 1. Loss of alpha1A receptor and MAPK signaling in the pre- and post-M myocardium. (A)
Reprehensive Western blots of MAKP signaling molecules in the myocardium from WT(sham, n = 4), AKO
(sham, n = 3), WT-MI (n = 6) and AKO-MI (n = 5). (B-I) Analyses & comparison of expression of MAPK
molecules in the pre-MI (sham) and post-MI myocardium, normalized to GAPDH protein levels. *P<0.05,
#P<0.01.
https://doi.org/10.1371/journal.pone.0188471.g001
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p38 continued to be higher in the non-infarcted myocardium of post-MI AKO mice compared
to post-MI WT mice (p<0.05, Fig 1), p38 activation (i.e. phosphorylation) was not.
Effect of loss of alpha1A receptor on LV remodeling
Although the alpha1-AR has been associated with the induction of physiologic hypertrophy [3,
4], the loss of alpha1A receptors was associated with a paradoxical increase of hypertrophy in
AKO vs. WT hearts. Numeric but non-significant increases in LV mass were observed in AKO
even prior to MI (Table 1), but differences in both LV mass (Table 1) and cardiac myocyte size
(Fig 2A) were significant compared to WT at 4 weeks post-MI. However, these reflections of
increased cardiac hypertrophy in AKO mice were also associated with increases in end systolic
and diastolic volumes (Table 1), suggesting that a possible reduction in alpha1A-AR-stimulated
physiologic hypertrophy led instead to an increase in pathologic hypertrophy and subsequently
to worsened post-MI ventricular dilatation. These observations were further corroborated by a
significant increase in the heart weight:body weight ratio of AKO mice 4 weeks after MI com-
pared to WT controls (Table 1).
Global ejection fraction (EF) and local fractional shortening (FS) at the level of the papillary
muscles was already substantially depressed in post-MI WT hearts, and was not lower in AKO
mice. Myocardial fibrosis, however, was noted to be substantially worse in the myocardium
remote to the infarcts in AKO vs. WT mice (Fig 2B).
Alpha1A-AR knockout was also associated with an increase in both the betaMHC/
alphaMHC mRNA expression ratio and in the mRNA expression of ANP (Fig 2C and 2D),
changes that would be consistent with a pattern of increased cardiac fetal gene expression that
has been linked to pathologic remodeling.
Effect of loss of alpha1A receptor on mortality
The exacerbation of post-MI remodeling in AKO mice was associated with a significant
increase in mortality rate compared to that of littermate WT controls at 4 weeks post-MI
(Fig 3, AKO mortality of 64%, n = 25, vs. 25% in WT, n = 32, P = 0.016). Mortality was not
observed in sham controls in either the AKO or WT groups. Five animals died before reaching
euthanasia criteria despite close monitoring on a twice-daily basis. In other cases, necropsy
reflected changes in the lungs and liver consistent with end stage heart failure.
Table 1. Cardiac function, hypertrophy and dilatation in WT and AKO mice 4 weeks post-MI.
WT AKO
Sham Vehicle Captopril Sham Vehicle Captopril
EF (%) 72±1 58±2 59±3 71±1 58±2* 67±1*
FS (%) 44±1 32±1 31±2 43±1 31±2* 37±1*
LVVtotal (uL) 118±11 151±11† 129±11 133±13 179±16*† 109±6*
LVEDV (uL) 50±6 70±7† 67±7 53±5 88±11*† 52±4*
LVESV (uL) 14±1 32±5† 29±5 15±1 42±7*† 17±2*
LVmass(uL) 71±6 85±4† 64±4 84±9 96±6*† 60±3*
HW:BW 5.2±0.2 6.4±0.1*† 5.4±0.2* 5.3±0.1 7.1±0.3*† 4.9±0.6*
n 5 28 (19) 10 5 28 (18) 9
*P<0.05, Vehicle vs. Captopril
†P<0.05 WTVehicle vs. AKOVehicle.
Sham = sham operated, non-infarcted mice. () = n for HW:BW measurements.
https://doi.org/10.1371/journal.pone.0188471.t001
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Effect of loss of alpha1A receptor leads to increased pro-apoptotic
signaling in the non-infarcted myocardium
During post-MI remodeling, cardiomyocytes in the remote, uninfarcted region experience
stresses resulting both from altered ventricular geometry and from the loss of contractile func-
tion in the infracted myocardium. Increased apoptosis rates have been observed as a part of
this myocardial stress response [2,21,22], and this cellular loss likely contributes to myocardial
fibrosis and to an ongoing decline in compensatory function of the remaining viable myocar-
dium. Loss of alpha1A-AR led to a significant drop in anti-apoptotic Bcl-2 protein and an
increase in pro-apoptotic Bax protein in post-MI AKO hearts. Similarly, apoptosis mediator
caspase 3 was increased in AKO hearts compared to post-MI WT controls (Fig 4A–4H).
TUNEL staining corroborated a subsequent increase in apoptotic nuclei in the remote myo-
cardium of these AKO hearts (Fig 4I).
Fig 2. Effect of loss of alpha1A receptor on LV remodeling at 4 weeks post-MI. (A) Myocyte surface area revealed by WGA staining, n = 4–5,
bar = 20 μm. (B) Fibrosis as measured Sirius Red collagen staining, n = 5–9. betaMHC/alphaMHC mRNA ratio (C) and ANP mRNA expression (D)
in the 4-week post-MI myocardium. AKO mice exhibited a significantly higher betaMHC/alphaMHC ratio as well as ANP mRNA expression than WT
mice, while captopril treatment eliminated the difference between them. Captopril significantly reduced ANP expression in both WT and AKO mice,
but reduced the betaMHC/alphaMHC ratio only in AKO mice. Number of mice analyzed in each group: WT-vehicle = 7, AKO-vehicle = 9,
WT-Captopril = 10, AKO-Captopril = 9. *P<0.05, #P<0.01.
https://doi.org/10.1371/journal.pone.0188471.g002
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ACE inhibitor captopril reverses the effects of alpha1A-AR deficiency in
the post-MI mouse myocardium
To further explore the role of exacerbated pathologic remodeling after MI in the absence of the
alpha1A-AR, we investigated the effect of angiotensin converting enzyme (ACE) inhibitor cap-
topril, known to inhibit pathologic ventricular hypertrophy, after LAD ligation. Although cap-
topril reduced 4-week post-MI mortality in both AKO and WT mice compared to vehicle
controls (Fig 3), this effect was most profound in AKO mice in which mortality was reduced
from 64% to 18% (P = 0.01). Effects on mortality were related to an impact of ACE inhibition
on cardiac remodeling. Although modest improvements in LV hypertrophy and dilatation
were observed with post-MI captopril treatment of WT mice, more dramatic improvements in
LV mass, LV end-systolic and end-diastolic volumes, and heart weight:body weight ratios were
observed in the AKO hearts (Table 1). Furthermore, although local and global contractility
post-MI, as reflected in measurements of FS and EF, respectively, were not lower in vehicle-
treated AKO than in vehicle-treated WT mice, significant improvement was seen only in the
AKO mice after ACE inhibition.
Captopril significantly decreased the expression of ANP mRNA, but not the betaMHC/
alphaMHC mRNA ratio, in the remote myocardium of WT mice 4 weeks after LAD ligation
Fig 3. Post-MI survival of WT and AKO mice with or without captopril treatment. AKO mice experienced significantly higher mortality than WT
(WT-vehicle vs. AKO-vehicle, P = 0.016). Captopril improved post-MI survival in both WT and AKO mice (WT-vehicle VS. WT-Captopril, P = 0.052;
AKO-vehicle VS. AKO-Captopril, P = 0.012), and minimized the mortality difference between WT and AKO (WT-Captopril VS. AKO-Captopril,
P = 0.1473). Number of mice analyzed in each group: WT-vehicle = 32, AKO-vehicle = 25, WT-Captopril = 11, AKO-Captopril = 11.
https://doi.org/10.1371/journal.pone.0188471.g003
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(Fig 2C and 2D). However, much more dramatic changes in ANP mRNA expression and a
large, highly significant decrease in the betaMHC/alphaMHC mRNA ratio was observed with
captopril treatment of post-MI AKO mice (P<0.01). Interestingly, captopril inhibition of the
fetal gene program reduced fetal gene expression levels in the AKO to below those of littermate
WT controls.
Discussion
We have previously hypothesized that different forms of myocardial stress result in a differen-
tial induction of pathways that mediate either a physiologic, reversible, adaptive hypertrophic
response (e.g., exercise, pregnancy), or a pathologic, maladaptive hypertrophic response that
inevitably leads to decompensatory remodeling and ventricular failure (e.g., volume overload,
MI) [2]. We have further postulated that a balance between these molecular regulatory
responses within cardiac myocytes determines the fate of the stressed myocardium, and that a
therapeutic opportunity therefore exists to affect this balance and shift it toward a physiologic
adaptive signaling pattern even under disease conditions.
Previous studies have documented the potential benefit from supraphysiologic alpha1AR
gain-of-function during pathologic remodeling after MI and during doxorubicin-induced car-
diomyopathy [15, 23]. In the present study, however, we have exploited a unique loss-of-
Fig 4. Regulation of apoptosis in the AKO myocardium 4 weeks after MI. (A) Western blots of apoptosis regulators. (B-H) Expression of
apoptosis regulators in WT and AKO mice. The anti-apoptotic Bcl-2 is significantly lower in AKO than in WT mice in the non-infarcted myocardium,
while the pro-apoptotic Bax and caspase 3 (p20) are significantly higher in AKO (*P<0.05). (I) TUNEL staining in the non-infarcted myocardium 4
weeks post-MI. Post-MI apoptosis rates were measured as the percentage of TUNEL-positive nuclei in the myocardium (*P<0.05); representative
micrographs are presented from TUNEL-stained WT and AKO hearts. Number of mice analyzed in each group: WT-MI = 6, AKO-MI = 4.
https://doi.org/10.1371/journal.pone.0188471.g004
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function model to demonstrate the critical physiological role that alpha1AR and downstream
MEK-ERK signaling plays in determining the balance between physiologic and pathologic
response to stress after MI. In fact, we have furthered the potential therapeutic goal of manipu-
lating this balance via documentation of the role that alpha1-adrenergic signaling, associated
in the past with adaptive hypertrophy, likely plays in ameliorating the negative impact of a
maladaptive response to the pathologic stresses of the post-MI myocardium. In the absence of
MI, the AKO demonstrated normal cardiac function and physiological characteristics. How-
ever, there was a significant increase in phospho-p38 (23-fold), phospho-MEK1 (1.4-fold) and
MKP1 (1.8-folds). Coupled with a numeric but non-significant increase in echocardiographic
measurement of LV mass, these data suggest a possible compensatory increase in pathologic
hypertrophy even without MI in the absence of alpha1AR signaling.
ACE inhibition has been well documented to dampen pathologic hypertrophy through its
modulation of the rennin-angiotensin system. We therefore treated AKO mice and their litter-
mate WT controls with captopril to further test our hypothesis that the loss of alpha1AR-medi-
ated adaptive hypertrophy led to a corresponding increase in pathologic hypertrophy in
response to the various stresses experienced by the post-MI myocardium. Although ACE inhi-
bition did have an expected ameliorative effect on WT hearts, in general the physiologic, ana-
tomic and clinical benefits were substantially increased in the AKO mice, suggesting that
pathologic hypertrophy had, in fact, played a more prominent role in their manifestation of
post-MI remodeling.
It has been known for some time that specific loss of alpha adrenergic signaling can contrib-
ute to human cardiac pathophysiology. The ALHAT and V-HeFT studies, for example, indicated
that alpha adrenergic blockade worsens outcomes in the clinical contexts of hypertension and
heart failure, respectively [24,25]. Baseline changes in molecular signaling in the AKO mice,
even prior to MI, including a substantial increase in the pro-inflammatory and pro-apoptotic
regulator phopho-p38 [21,26], might have predisposed the AKO myocardium to stress-induced
injury. MI induced both phosphorylation of MEK1 (ERK1/2 activator) but also an increase in
the ERK1/2-inactivating phosphatase MKP3; as a result we did not observe an increase in ERK1/
2 activation in the post-MI, remote, non-infarcted WT myocardium. ERK1/2 phosphorylation,
however, was significantly lower post-MI in AKO than in WT, as was the phospho-ERK1/2:total
ERK1/2 ratio.
These changes in MAPK signaling pathways in the AKO myocardium suggest that
alpha1AR may contribute to the regulation and amelioration of cardiac responses under stress.
In fact, loss of just the specific alpha1A adrenergic subtype significantly worsened ventricular
pathologic remodeling via a paradoxical increase in pathologic hypertrophy and subsequent
dilatation. Loss of the alpha1A-AR also led to an increase in apoptosis and fibrosis of the unin-
farcted remote myocardium, and resulted in substantially higher post-MI mortality. These
findings corroborate our hypothesized role of a balance between pro-adaptive and maladaptive
signaling in determining the course of post-MI remodeling, and lay a stronger foundation for
seeking therapeutic alteration of this balance as a novel approach to preventing heart failure
after MI.
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